VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2022 | Neuromodulation techniques in Parkinson’s disease: DBS & TMS

Lars Wojtecki, MD, PhD, Institute of Clinical Neuroscience and Medical Psychology, University Düsseldorf, Düsseldorf, Germany, shares updates on neuromodulation for Parkinson’s disease. Many research groups continue to focus on invasive interventions, including deep brain stimulation (DBS). In the space of non-invasive approaches, there are ongoing studies evaluating the safety and feasibility of transcranial magnetic stimulation (TMS) in patients with Parkinson’s disease, and updates are expected shortly. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.

Disclosures

Grants/Institutional Support: Hilde Ulrichs Stiftung für Parkinsonforschung, ParkinsonFonds Deutschland, BMBF/ERA-NETNEURON, DFG Forschergruppe (FOR1328), Deutsche Parkinson Vereinigung (DPV), Forschungskommission, Medizinische Fakultät, HHU Düsseldorf, UCB; Medtronic, UCB, Teva, Allergan, Merz, Abbvie, Roche, Bial, Merck, Novartis, Desitin, Spectrum;
Honorary/Travel Grants/Consultancy: TEVA, UCB Schwarz, Desitin, Medtronic, Abbott/Abbvie, MEDA, Boehringer I, Storz Medical, Kyowa Kirin, Guidepoint, Merck, Merz, Synergia, BIAL, Zambon, Sapio Life, STADA, Inomed, Vertanical;
Stock Ownership: BioNTech.